IN2012MN02812A - - Google Patents

Info

Publication number: IN2012MN02812A
Authority: IN; India
Prior art keywords: interleukin; growth factor; alpha; apolipoprotein; insulin
Prior art date: 2010-06-23

Application number

Other languages

English (en)

Inventor

Joseph Anderberg

Jeff Gray

Paul Mcpherson

Kevin Nakamura

James Patrick Kampf

Original Assignee

Astute Medical Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-23

Filing date

2011-06-23

Publication date

2015-05-22

2011-06-23 Application filed by Astute Medical Inc filed Critical Astute Medical Inc

2015-05-22 Publication of IN2012MN02812A publication Critical patent/IN2012MN02812A/en

Links

206010061481 Renal injury Diseases 0.000 abstract 3
102100029470 Apolipoprotein E Human genes 0.000 abstract 1
101710095339 Apolipoprotein E Proteins 0.000 abstract 1
102000007592 Apolipoproteins Human genes 0.000 abstract 1
108010071619 Apolipoproteins Proteins 0.000 abstract 1
102100021935 C-C motif chemokine 26 Human genes 0.000 abstract 1
101710112537 C-C motif chemokine 26 Proteins 0.000 abstract 1
102100032366 C-C motif chemokine 7 Human genes 0.000 abstract 1
101710155834 C-C motif chemokine 7 Proteins 0.000 abstract 1
102100033777 Complement C4-B Human genes 0.000 abstract 1
108010077762 Complement C4b Proteins 0.000 abstract 1
102400000739 Corticotropin Human genes 0.000 abstract 1
101800000414 Corticotropin Proteins 0.000 abstract 1
102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 abstract 1
108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 abstract 1
102000004369 Insulin-like growth factor-binding protein 4 Human genes 0.000 abstract 1
108090000969 Insulin-like growth factor-binding protein 4 Proteins 0.000 abstract 1
108010078049 Interferon alpha-2 Proteins 0.000 abstract 1
102100039350 Interferon alpha-7 Human genes 0.000 abstract 1
102100020989 Interferon lambda-2 Human genes 0.000 abstract 1
101710099622 Interferon lambda-2 Proteins 0.000 abstract 1
102100030704 Interleukin-21 Human genes 0.000 abstract 1
102000011718 Interleukin-23 Subunit p19 Human genes 0.000 abstract 1
108010076561 Interleukin-23 Subunit p19 Proteins 0.000 abstract 1
108010067003 Interleukin-33 Proteins 0.000 abstract 1
102000017761 Interleukin-33 Human genes 0.000 abstract 1
102000012347 Interleukin-4 Receptor alpha Subunit Human genes 0.000 abstract 1
108010061858 Interleukin-4 Receptor alpha Subunit Proteins 0.000 abstract 1
102100040947 Lutropin subunit beta Human genes 0.000 abstract 1
101710183224 Lutropin subunit beta Proteins 0.000 abstract 1
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 abstract 1
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 abstract 1
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 abstract 1
108050003738 Neural cell adhesion molecule 1 Proteins 0.000 abstract 1
102100035846 Pigment epithelium-derived factor Human genes 0.000 abstract 1
102000007066 Prostate-Specific Antigen Human genes 0.000 abstract 1
108010072866 Prostate-Specific Antigen Proteins 0.000 abstract 1
108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 abstract 1
102100029530 Thyrotropin subunit beta Human genes 0.000 abstract 1
101710087584 Thyrotropin subunit beta Proteins 0.000 abstract 1
102000002248 Thyroxine-Binding Globulin Human genes 0.000 abstract 1
108010000259 Thyroxine-Binding Globulin Proteins 0.000 abstract 1
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 abstract 1
101710165436 Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 abstract 1
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 1
108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 abstract 1
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 abstract 1
102000013529 alpha-Fetoproteins Human genes 0.000 abstract 1
108010026331 alpha-Fetoproteins Proteins 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 abstract 1
229960000258 corticotropin Drugs 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
239000000104 diagnostic biomarker Substances 0.000 abstract 1
239000000539 dimer Substances 0.000 abstract 1
108010074108 interleukin-21 Proteins 0.000 abstract 1
208000037806 kidney injury Diseases 0.000 abstract 1
239000003550 marker Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
238000012544 monitoring process Methods 0.000 abstract 1
108090000102 pigment epithelium-derived factor Proteins 0.000 abstract 1
238000004393 prognosis Methods 0.000 abstract 1
239000000092 prognostic biomarker Substances 0.000 abstract 1
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 abstract 1
238000011269 treatment regimen Methods 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Cell Biology (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Biophysics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

IN2812MUN2012 2010-06-23 2011-06-23 IN2012MN02812A (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US35796510P	2010-06-23	2010-06-23
US35795610P	2010-06-23	2010-06-23
US35796610P	2010-06-23	2010-06-23
US36429610P	2010-07-14	2010-07-14
US36430510P	2010-07-14	2010-07-14
PCT/US2011/001125 WO2011162819A1 (fr)	2010-06-23	2011-06-23	Méthodes et compositions pour diagnostiquer et pronostiquer une lésion rénale et une insuffisance rénale

Publications (1)

Publication Number	Publication Date
IN2012MN02812A true IN2012MN02812A (fr)	2015-05-22

Family

ID=45371737

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN2812MUN2012 IN2012MN02812A (fr)	2010-06-23	2011-06-23

Country Status (7)

Country	Link
US (4)	US20130203074A1 (fr)
EP (2)	EP3339859A1 (fr)
AU (1)	AU2011269847A1 (fr)
CA (1)	CA2803498A1 (fr)
IN (1)	IN2012MN02812A (fr)
NZ (2)	NZ605561A (fr)
WO (1)	WO2011162819A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201214440D0 (en) *	2012-08-13	2012-09-26	Randox Lab Ltd	Kidney disease biomarker
EA201790696A1 (ru) *	2014-10-20	2017-10-31	Астьют Медикал, Инк.	Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
US11143658B2 (en)	2015-05-12	2021-10-12	Astute Medical, Inc.	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11353465B2 (en)	2017-01-12	2022-06-07	Astute Medical, Inc.	Methods and compositions for evaluation and treatment of renal injury and renal failure based on C—C motif chemokine ligand 14 measurement
EP3571222A4 (fr) *	2017-01-19	2021-06-16	Cedars-Sinai Medical Center	Procédés à base de spectrométrie de masse et hautement multiplexés permettant de mesurer 72 protéines humaines

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU1429031A1 (ru)	1986-06-20	1988-10-07	Калининский Государственный Медицинский Институт	Способ дифференциальной диагностики гломерулонефрита и пиелонефрита
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5939272A (en)	1989-01-10	1999-08-17	Biosite Diagnostics Incorporated	Non-competitive threshold ligand-receptor assays
US5028535A (en)	1989-01-10	1991-07-02	Biosite Diagnostics, Inc.	Threshold ligand-receptor assay
US5922615A (en)	1990-03-12	1999-07-13	Biosite Diagnostics Incorporated	Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (fr)	1990-09-14	1992-03-15	Kenneth Francis Buechler	Anticorps liant aux complexes de recepteurs de ligands et de ligands et leur utilite dans les tests ligand-recepteur
US5955377A (en)	1991-02-11	1999-09-21	Biostar, Inc.	Methods and kits for the amplification of thin film based assays
AU1772992A (en)	1991-04-10	1992-11-17	Biosite Diagnostics Incorporated	Crosstalk inhibitors and their uses
EP0579767B1 (fr)	1991-04-11	2000-08-23	Biosite Diagnostics Inc.	Nouveaux conjugues et dosages destines a la detection simultanee de ligands multiples
US6143576A (en)	1992-05-21	2000-11-07	Biosite Diagnostics, Inc.	Non-porous diagnostic devices for the controlled movement of reagents
US6019944A (en)	1992-05-21	2000-02-01	Biosite Diagnostics, Inc.	Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US5494829A (en)	1992-07-31	1996-02-27	Biostar, Inc.	Devices and methods for detection of an analyte based upon light interference
US5824799A (en)	1993-09-24	1998-10-20	Biosite Diagnostics Incorporated	Hybrid phthalocyanine derivatives and their uses
US6498142B1 (en)	1996-05-06	2002-12-24	Curis, Inc.	Morphogen treatment for chronic renal failure
JP4602482B2 (ja)	1996-05-24	2010-12-22	バイオジェン・アイデック・エムエイ・インコーポレイテッド	組織再生のモジュレーター
US5753455A (en)	1996-09-03	1998-05-19	Bayer Corporation	Method for the detection of lysozyme using a protein error indicator dye in conjunction with an alkane sulfonic acid
US6113855A (en)	1996-11-15	2000-09-05	Biosite Diagnostics, Inc.	Devices comprising multiple capillarity inducing surfaces
US5947124A (en)	1997-03-11	1999-09-07	Biosite Diagnostics Incorporated	Diagnostic for determining the time of a heart attack
US6057098A (en)	1997-04-04	2000-05-02	Biosite Diagnostics, Inc.	Polyvalent display libraries
WO1998055508A2 (fr)	1997-06-03	1998-12-10	Sagami Chemical Research Center	Proteines humaines ayant des domaines transmembranaires et adn codant ces proteines
US20060223077A1 (en)	1997-06-06	2006-10-05	Human Genome Sciences, Inc.	207 human secreted proteins
US6218122B1 (en) *	1998-06-19	2001-04-17	Rosetta Inpharmatics, Inc.	Methods of monitoring disease states and therapies using gene expression profiles
US6958147B1 (en)	1998-10-26	2005-10-25	Licentia Ltd	Use of VEGF-C to prevent restenosis
IL143892A0 (en)	1998-12-21	2002-04-21	Univ Monash	Kidney disease detection and treatment
RU2180965C1 (ru)	2000-07-03	2002-03-27	Габбасова Наталья Вадимовна	Способ дифференциальной диагностики заболеваний почек
AU2002216273A1 (en)	2000-12-29	2002-07-16	Oxford Glycosciences (Uk) Limited	Proteins, genes and their use for diagnosis and treatment of kidney response
US20060088823A1 (en)	2001-03-29	2006-04-27	Brian Haab	Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification
US20070015146A1 (en)	2001-05-22	2007-01-18	Gene Logic, Inc.	Molecular nephrotoxicology modeling
US7235358B2 (en)	2001-06-08	2007-06-26	Expression Diagnostics, Inc.	Methods and compositions for diagnosing and monitoring transplant rejection
US20030003588A1 (en)	2001-06-28	2003-01-02	Comper Wayne D.	Method for kidney disease detection by protein profiling
CA2454342A1 (fr)	2001-07-24	2003-02-06	Yale University	Procedes, compositions et necessaires relatifs a des molecules chitinases et de type chitinase ainsi qu'a des maladies inflammatoires
US6784154B2 (en)	2001-11-01	2004-08-31	University Of Utah Research Foundation	Method of use of erythropoietin to treat ischemic acute renal failure
US8404229B2 (en)	2001-12-07	2013-03-26	Cytori Therapeutics, Inc.	Methods of using adipose derived stem cells to treat acute tubular necrosis
GB0130557D0 (en)	2001-12-20	2002-02-06	Serono Internat S A	Proteins
US20070233391A1 (en)	2002-03-07	2007-10-04	Cambridge University Technical Service Limited (CUTS)	Scd fingerprints
EP1532268A4 (fr)	2002-03-21	2006-07-05	Yissum Res Dev Co	Marqueurs de cellules sanguines peripheriques utiles pour le diagnostic de la sclerose en plaques et procedes et trousses comprenant de tels marqueurs
US7138230B2 (en)	2002-12-06	2006-11-21	Renovar, Inc.	Systems and methods for characterizing kidney diseases
US7138229B2 (en)	2002-12-06	2006-11-21	Renovar, Inc.	Systems and methods for characterizing kidney diseases
WO2004005934A2 (fr)	2002-07-04	2004-01-15	Oxford Glycosciences (Uk) Ltd	Marqueurs de toxicite
US6941172B2 (en)	2002-11-18	2005-09-06	Zvi Nachum	Method and device for restoring kidney function using electromagnetic stimulation
US20060063156A1 (en)	2002-12-06	2006-03-23	Willman Cheryl L	Outcome prediction and risk classification in childhood leukemia
CN1791797A (zh)	2003-03-27	2006-06-21	儿童医院医疗中心	用于检测肾小管细胞损伤的早发的方法和试剂盒
DE602004022150D1 (de)	2003-03-27	2009-09-03	Childrens Hosp Medical Center	Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
KR101224235B1 (ko)	2003-04-11	2013-01-25	메디뮨 엘엘씨	재조합 ｉｌ９ 항체 및 그의 용도
US7560244B2 (en)	2003-06-04	2009-07-14	Joslin Diabetes Center, Inc.	Method of evaluating a subject for risk or predisposition of reduced renal function over time
US20050148029A1 (en)	2003-09-29	2005-07-07	Biosite, Inc.	Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
GB0329288D0 (en)	2003-12-18	2004-01-21	Inverness Medical Switzerland	Monitoring method and apparatus
CA2560200A1 (fr)	2004-03-17	2005-09-22	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Ciblage de cd44 destine a reduire/prevenir des lesions par ischemie-reperfusion
US20060204951A1 (en)	2004-04-26	2006-09-14	Judah Folkman	Platelet biomarkers for the detection of disease
US20050272101A1 (en)	2004-06-07	2005-12-08	Prasad Devarajan	Method for the early detection of renal injury
US7588892B2 (en)	2004-07-19	2009-09-15	Entelos, Inc.	Reagent sets and gene signatures for renal tubule injury
WO2006008661A2 (fr)	2004-07-19	2006-01-26	Neurochem (International) Limited	Methodes diagnostiques d'amylose affectant de multiples organes
US7141382B1 (en)	2004-10-12	2006-11-28	Parikh Chirag R	Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
WO2006044779A1 (fr)	2004-10-14	2006-04-27	Northwestern University	Detection et traitement du cancer renal
WO2006083986A2 (fr)	2005-02-01	2006-08-10	Government Of The U.S.A, As Represented By The Secretary Department Of Health & Human Services	Biomarqueurs de statut tissulaire
EP2604703B1 (fr)	2005-03-14	2017-02-01	The Board of Trustees of the Leland Stanford Junior University	Procédés permettant d'évaluer la survie d'un greffon chez un destinataire d'une transplantation d'organe solide
US7608413B1 (en)	2005-03-25	2009-10-27	Celera Corporation	Kidney disease targets and uses thereof
US20070037232A1 (en)	2005-03-31	2007-02-15	Barasch Jonathan M	Detection of NGAL in chronic renal disease
NZ562928A (en)	2005-04-18	2011-01-28	Mitomics Inc	Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US20070087387A1 (en)	2005-04-21	2007-04-19	Prasad Devarajan	Method for the Early Detection of Renal Disease Using Proteomics
WO2007013919A2 (fr)	2005-07-21	2007-02-01	The Johns Hopkins University	Insuffisance renale aigue
US7759077B2 (en)	2005-08-02	2010-07-20	Shariat Shahrokh F	Soluble fas urinary marker for the detection of bladder transitional cell carcinoma
EP1757940A1 (fr)	2005-08-26	2007-02-28	Cézanne S.A.S.	In-vitro méthode pour la diagnose et surveillance du carcinome cellulaire renal en utilisant MMP-7 comme biomarqueur humoral
CA2624569A1 (fr)	2005-10-03	2007-04-12	Biosite Incorporated	Methodes et compositions utiles dans le diagnostic et/ou le pronostic des syndromes de reponse inflammatoire systemique
US20080090304A1 (en)	2006-10-13	2008-04-17	Barasch Jonathan Matthew	Diagnosis and monitoring of chronic renal disease using ngal
US8329408B2 (en)	2005-10-31	2012-12-11	Bayer Healthcare Llc	Methods for prognosis and monitoring cancer therapy
US10716749B2 (en)	2005-11-03	2020-07-21	Palo Alto Investors	Methods and compositions for treating a renal disease condition in a subject
US20080133141A1 (en)	2005-12-22	2008-06-05	Frost Stephen J	Weighted Scoring Methods and Use Thereof in Screening
TW200726845A (en)	2006-01-02	2007-07-16	Nat Defense Medical Ct	Biomarker molecular of renal illness and detecting method for the same
GB0605217D0 (en)	2006-03-15	2006-04-26	Novartis Ag	Method and compositions for assessing acute rejection
GB0606776D0 (en)	2006-04-03	2006-05-10	Novartis Pharma Ag	Predictive biomarkers for chronic allograft nephropathy
US7662578B2 (en)	2006-04-21	2010-02-16	Children's Hospital Medical Center	Method and kit for the early detection of impaired renal status
US20080038269A1 (en)	2006-05-25	2008-02-14	Mount Sinai Hospital	Methods for detecting and treating kidney disease
WO2008084331A2 (fr)	2006-06-21	2008-07-17	Hopitaux Universitaires De Geneve	Biomarqeurs pour des troubles rénaux
US20090298073A1 (en)	2006-06-30	2009-12-03	Gerhold David L	Kidney Toxicity Biomarkers
US20090176656A1 (en)	2006-07-21	2009-07-09	Halloran Philip F	Tissue rejection
GB0617429D0 (en)	2006-09-05	2006-10-18	Electrophoretics Ltd	Markers of renal transplant rejection and renal damage
US20080206794A1 (en)	2006-09-15	2008-08-28	Renovar Incorporated	Systems And Methods For Characterizing Contrast Induced-Nephropathy
US7842472B2 (en)	2006-11-14	2010-11-30	Alere International	Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
CA2665489C (fr)	2006-12-08	2017-08-29	The Children's Hospital Of Philadelphia	Compositions associees a prrg4 et procedes d'utilisation de celles-ci dans des procedes de diagnostic de tumeur
GB0701626D0 (en)	2007-01-22	2007-03-07	Cambridge Entpr Ltd	Methods and biomarkers for diagnosing and monitoring psychotic disorders
WO2008104803A2 (fr)	2007-02-26	2008-09-04	Oxford Genome Sciences (Uk) Limited	Protéines
US8221995B2 (en)	2007-03-23	2012-07-17	Seok-Won Lee	Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
EP2479571A3 (fr)	2007-03-26	2012-09-26	Novartis AG	Biomarqueurs de sécurité rénale prédictive et signatures de biomarqueur pour surveiller la fonction rénale
WO2008122670A2 (fr)	2007-04-10	2008-10-16	Integragen	Gène tnfrsf10b de susceptibilité au diabète chez l'homme
US8080394B2 (en)	2007-04-27	2011-12-20	Brigham And Women's Hospital	Method for determining predisposition to pulmonary infection
WO2008150488A1 (fr)	2007-06-01	2008-12-11	Laboratory Corporation Of America Holdings	Procédés et systèmes de quantification de peptides et d'autres analytes
WO2008154238A1 (fr)	2007-06-06	2008-12-18	Siemens Healthcare Diagnostics Inc.	Diagnostics prédictifs pour maladie rénale
US20090047689A1 (en)	2007-06-20	2009-02-19	John Kolman	Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
US20100267041A1 (en)	2007-09-14	2010-10-21	Predictive Biosciences, Inc.	Serial analysis of biomarkers for disease diagnosis
EP2203743A4 (fr)	2007-09-20	2011-03-02	Univ Louisville Res Found	Biomarqueurs peptidiques prédictifs d'un déclin de la fonction rénale et d'une maladie des reins
US20110059537A1 (en)	2007-09-20	2011-03-10	Caritas St. Elizabeth's Medical Center Of Boston, Inc.	Method for estimating risk of acute kidney injury
US8003333B2 (en)	2007-09-28	2011-08-23	Mayo Foundation For Medical Education And Research	Serum biomarkers for early detection of acute cellular rejection
CN101960308B (zh)	2008-02-29	2014-07-09	国立大学法人名古屋大学	急性肾损伤及预后推测用生物标记物以及其用途
CN101358976A (zh)	2008-04-28	2009-02-04	北京华大吉比爱生物技术有限公司	检测六项肿瘤标志物的微阵列-酶联免疫检测试剂盒
US20090298106A1 (en)	2008-05-30	2009-12-03	Therapeutic Monitoring Services, L.L.C.	Methods for Monitoring Immunosuppressant Drug Levels, Renal Function, and Hepatic Function Using Small Volume Samples
US8241861B1 (en)	2008-07-08	2012-08-14	Insilicos, Llc	Methods and compositions for diagnosis or prognosis of cardiovascular disease
US7998744B2 (en)	2008-07-28	2011-08-16	Greenwood Genetic Center, Inc.	Methods for determining dysregulation of methylation of brain expressed genes on the X chromosome to diagnose autism spectrum disorders
WO2010022210A2 (fr)	2008-08-21	2010-02-25	Pxbiosciences Llc	Diagnostic et surveillance de l’insuffisance rénale au moyen de biomarqueurs peptidiques
JP2012501456A (ja)	2008-08-28	2012-01-19	アスチュートメディカル，インコーポレイテッド	腎損傷および腎不全の診断および予後のための方法および組成物
CA2735590A1 (fr)	2008-08-29	2010-03-04	Astute Medical, Inc.	Procedes et compositions pour le diagnostic et le pronostic de la blessure renale et de l'insuffisance renale
US8501489B2 (en)	2008-09-26	2013-08-06	University of Pittsburgh—of the Commonwealth System of Higher Education	Urinary biomarkers to predict long-term dialysis
WO2010048346A1 (fr)	2008-10-21	2010-04-29	Astute Medical, Inc.	Procédés et compositions pour le diagnostic et le pronostic d’une lésion rénale et de l’insuffisance rénale
EP2767833A3 (fr)	2008-10-21	2014-12-17	Astute Medical, Inc.	Procédés et compositions pour le diagnostic et le pronostic de lésion rénale et d'insuffisance rénale
CN104330574B (zh)	2008-11-10	2017-04-12	阿斯图特医药公司	用于诊断和预后肾损伤和肾衰竭的方法和组合物
EP2364370B1 (fr)	2008-11-22	2014-09-03	Astute Medical, Inc.	Procédés pour le pronostic d'une insuffisance rénale acute
US9229010B2 (en)	2009-02-06	2016-01-05	Astute Medical, Inc.	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102439441B (zh)	2009-02-06	2016-03-09	阿斯图特医药公司	用于肾损伤和肾衰竭的诊断及预后方法和组合物
JP2012522491A (ja)	2009-04-03	2012-09-27	ベジニクスピーティーワイリミテッド	抗ｖｅｇｆ−ｄ抗体
WO2010128158A1 (fr)	2009-05-08	2010-11-11	Novartis Ag	Biomarqueurs diagnostiques pour des troubles fibrotiques
WO2011017685A1 (fr)	2009-08-07	2011-02-10	Rules-Based Medicine, Inc.	Méthodes et dispositifs permettant de détecter le rejet d'une greffe rénale
US20120315649A1 (en)	2009-08-28	2012-12-13	Astute Medical ,Inc. a corporation	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2774223A1 (fr)	2009-09-21	2011-03-24	Astute Medical, Inc.	Procedes et compositions de diagnostic et de pronostic de lesions et d'insuffisances renales
MX342967B (es)	2009-12-20	2016-10-19	Astute Medical Inc	Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
EP2539712A4 (fr)	2010-02-26	2013-09-18	Astute Medical Inc	Procédés et compositions pour diagnostic et pronostic de lésion rénale et d'insuffisance rénale
CN102539745B (zh)	2010-12-31	2013-03-06	中国人民解放军第三〇九医院	移植肾排斥反应早期诊断及预警试剂盒
US20130035290A1 (en)	2011-05-17	2013-02-07	Yale University	Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury

2011
- 2011-06-23 IN IN2812MUN2012 patent/IN2012MN02812A/en unknown
- 2011-06-23 AU AU2011269847A patent/AU2011269847A1/en not_active Abandoned
- 2011-06-23 CA CA2803498A patent/CA2803498A1/fr not_active Abandoned
- 2011-06-23 US US13/806,761 patent/US20130203074A1/en not_active Abandoned
- 2011-06-23 WO PCT/US2011/001125 patent/WO2011162819A1/fr not_active Ceased
- 2011-06-23 EP EP18150690.8A patent/EP3339859A1/fr not_active Withdrawn
- 2011-06-23 NZ NZ60556111A patent/NZ605561A/en not_active IP Right Cessation
- 2011-06-23 EP EP11798514.3A patent/EP2585825B1/fr not_active Not-in-force
- 2011-06-23 NZ NZ703055A patent/NZ703055A/en not_active IP Right Cessation
2017
- 2017-05-22 US US15/602,031 patent/US20170261519A1/en not_active Abandoned
2018
- 2018-12-31 US US16/237,479 patent/US10928403B2/en not_active Expired - Fee Related
2021
- 2021-01-20 US US17/153,200 patent/US20210148937A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2803498A1 (fr)	2011-12-29
EP2585825A4 (fr)	2013-12-11
NZ605561A (en)	2015-03-27
US10928403B2 (en)	2021-02-23
WO2011162819A1 (fr)	2011-12-29
EP2585825A1 (fr)	2013-05-01
US20170261519A1 (en)	2017-09-14
EP3339859A1 (fr)	2018-06-27
EP2585825B1 (fr)	2018-01-10
US20130203074A1 (en)	2013-08-08
AU2011269847A1 (en)	2013-01-31
US20210148937A1 (en)	2021-05-20
US20190265253A1 (en)	2019-08-29
NZ703055A (en)	2016-07-29

Publication	Publication Date	Title
Asayama et al.	2017	Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes
EP2585826A4 (fr)	2013-12-04	Méthodes et compositions pour diagnostiquer et pronostiquer une lésion rénale et une insuffisance rénale
MX2011004767A (es)	2011-09-06	Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
Tug et al.	2015	Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage
MX342967B (es)	2016-10-19	Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
Wendt et al.	2006	Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells
Dlouhy et al.	2017	High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma
NZ619883A (en)	2014-11-28	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
IN2014MN00377A (fr)	2015-06-19
BRPI1013688A8 (pt)	2017-02-14	Proteínas de ligação de il-17.
JP2008249727A5 (fr)	2008-12-04
BRPI0607490A2 (pt)	2009-09-08	anticorpos monoclonais antiinterferon alfa e métodos para uso
BRPI1007867B8 (pt)	2021-05-25	anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
IN2012DN01322A (fr)	2015-06-05
WO2007103770A8 (fr)	2007-12-13	Compositions et procedes pour l'analyse du cancer du rein
EA200701211A1 (ru)	2007-12-28	Полипептиды, которые связываются с br3, и их применение
Lemancewicz et al.	2013	Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features
RU2014132108A (ru)	2016-02-20	Slit-robo сигналинг для диагностики и лечения заболевания почек
Ushmorov et al.	2018	FOXO in B-cell lymphopoiesis and B cell neoplasia
BR112013021056A2 (pt)	2016-08-09	anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical
JP2007514651A5 (fr)	2007-09-13
WO2011097541A3 (fr)	2011-11-10	Procédés et compositions pour le diagnostic et le pronostic d'une lésion rénale et d'une insuffisance rénale
NZ598035A (en)	2014-06-27	Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2083018A3 (fr)	2010-05-05	Compositions et procédés associés à STOP-1
JP2016524611A (ja)	2016-08-18	がんを治療する方法